Hepcidin Modulators: A Potential Alternative Treatment of Iron Deficiency and Iron Deficiency Anemia in Heart Failure
Article Sidebar
Main Article Content
Abstract
Abstract
Heart failure affects roughly 6.7 million Americans and is associated with many comorbidities and complications, including iron deficiency and anemia. Iron homeostasis is integral to optimal body function. Hepcidin, a hepatically produced peptide, is a major modulator in iron homeostasis. Its synthesis is induced in part by inflammatory states. Iron deficiency in heart failure is currently diagnosed with the assessment of serum ferritin and percent of transferrin saturation. Iron deficiency in the setting of hepcidin excess in inflammatory conditions, such as heart failure, is discussed in this literature review. Iron deficiency is associated with worse prognosis and poorer outcomes in heart failure patients. Targeted treatment of iron deficiency and iron deficiency anemia may provide improved quality of life and decrease mortality and morbidity among heart failure patients. Current treatment options for iron deficiency and anemia include intravenous and oral iron supplementation, as well as other erythropoiesis-stimulating agents. However, concerns regarding safety have been raised in regards to these options. An emerging possibility for the treatment of iron deficiency in the setting of hepcidin overload is hepcidin modulators, including hepcidin antagonists or inhibitors. This review has addressed iron deficiency and anemia in heart failure and suggests that hepcidin antagonists/inhibitors may provide a viable alternative to the classic treatment methods.
Downloads
Article Details
Copyright (c) 2024 Lauren H, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16): e240-327. Available from: https://doi.org/10.1161/cir.0b013e31829e8776
Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412-1451. Available from: https://doi.org/10.1016/j.cardfail.2023.07.006
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18): e895-e1032. Available from: https://doi.org/10.1161/cir.0000000000001063
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392. Available from: https://doi.org/10.1001/jama.2009.2
Golla MSG, Shams P. Heart failure with preserved ejection fraction (HFpEF). In: StatPearls. StatPearls Publishing; 2024. Accessed September 22, 2024. Available from: http://www.ncbi.nlm.nih.gov/books/NBK599960/
Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33(16):2001-2006. Available from: https://doi.org/10.1093/eurheartj/ehq509
Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail. 2019;6(6):1105-1127. Available from: https://doi.org/10.1002/ehf2.12555
Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1-20. Available from: https://doi.org/10.1016/j.jchf.2012.10.002
Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92(10):1068-1078. Available from: https://doi.org/10.1002/ajh.24820
Han X, Chen X, Liu Y, Yang J, Nie W, Yang M, et al. Xinmailong injection on left ventricular remodeling and inflammatory mediators in patients with CHF: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1370448. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1370448/full
Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15(12):1350-1362. Available from: https://doi.org/10.1093/eurjhf/hft106
Wróbel-Nowicka K, Wojciechowska C, Jacheć W, Zalewska M, Romuk E. The role of oxidative stress and inflammatory parameters in heart failure. Medicina (Kaunas). 2024;60(5):760. Available from: https://doi.org/10.3390%2Fmedicina60050760
Smart NA, Steele M. The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review. Congest Heart Fail. 2011;17(3):110-114. Available from: https://doi.org/10.1111/j.1751-7133.2011.00217.x
Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324-1340. Available from: https://doi.org/10.1016/j.jacc.2020.01.014
Kang CK, Pope M, Lang CC, Kalra PR. Iron deficiency in heart failure: efficacy and safety of intravenous iron therapy. Cardiovasc Ther. 2017;35(6). Available from: https://doi.org/10.1111/1755-5922.12301
Classes and stages of heart failure. American Heart Association. Accessed September 21, 2024. Available from: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program. 2011;2011:538-542. Available from: https://doi.org/10.1182/asheducation-2011.1.538
Evaluation and management of anemia and iron deficiency in adults with heart failure - UpToDate. Accessed September 5, 2024. Available from: https://www-uptodate-com.proxy.rvu.edu/contents/evaluation-and-management-of-anemia-and-iron-deficiency-in-adults-with-heart-failure
Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica. 2013;98(11):1667-1676. Available from: https://doi.org/10.3324/haematol.2013.084624
Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol. 2011;54(1):173-181. Available from: https://doi.org/10.1016/j.jhep.2010.08.004
Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol. 2014;5:86. Available from: https://doi.org/10.3389/fphar.2014.00086
Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail. 2011;4(5):599-606. Available from: https://doi.org/10.1161/circheartfailure.111.960906
Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657-1665. Available from: https://doi.org/10.1016/j.jacc.2007.07.029
Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. Available from: https://doi.org/10.1016/j.ahj.2013.01.017
Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1). Available from: https://doi.org/10.1136/openhrt-2019-001012
Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023;74:261-277. Available from: https://doi.org/10.1146/annurev-med-043021-032816
Katsarou A, Pantopoulos K. Hepcidin therapeutics. Pharmaceuticals (Basel). 2018;11(4):127. Available from: https://doi.org/10.3390/ph11040127
Ginzburg YZ. Hepcidin and its multiple partners: complex regulation of iron metabolism in health and disease. Vitam Horm. 2023;123:249-284. Available from: https://doi.org/10.1016/bs.vh.2023.03.001
Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485-2489. Available from: https://doi.org/10.1016/j.jacc.2006.08.034
Jankowska EA, Rozentryt P, Witkowska A, Leonti A, Tsolakis E, Drakos SG, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872-1880. Available from: https://doi.org/10.1093/eurheartj/ehq158
Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241-1251. Available from: https://doi.org/10.1016/j.jacc.2011.04.040
Anand IS. Anemia and chronic heart failure: implications and treatment options. J Am Coll Cardiol. 2008;52(7):501-511. Available from: https://doi.org/10.1016/j.jacc.2008.04.044
Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232-2237. Available from: https://doi.org/10.1093/eurheartj/ehi388
Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation. 2003;107(2):223-225. Available from: https://doi.org/10.1161/01.cir.0000052622.51963.fc
Anand IS, Rector TS. Pathogenesis of anemia in heart failure. Circ Heart Fail. 2014;7(5):699-700. Available from: https://doi.org/10.1161/circheartfailure.114.001645
Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, et al. Detection, evaluation, and management of preoperative anemia in the elective orthopedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106(1):13d-22. Available from: https://doi.org/10.1093/bja/aeq361
Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation-driven pathophysiology of iron homeostasis: mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732. Available from: https://doi.org/10.3390/nu13113732
van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, et al. Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study: clinical and prognostic associations. Circ Heart Fail. 2018;11(2). Available from: https://doi.org/10.1161/circheartfailure.117.004431
Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med. 2003;35(8):578-591. Available from: https://doi.org/10.1080/07853890310016342
Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-1044. Available from: https://doi.org/10.1172/jci15686
Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616-3624. Available from: https://doi.org/10.1182/blood-2009-09-245977